Navigation Links
Keryx Biopharmaceuticals, Inc. Initiates Phase 3 Registration Trial of KRX-0401 (Perifosine) for Treatment of Patients with Advanced Multiple Myeloma
Date:12/16/2009

ll differentiation and cell survival. KRX-0401 is currently in a Phase 3 trial, under Special Protocol Assessment (SPA), in multiple myeloma, and in Phase 2 clinical development for several other tumor types. Keryx is also developing Zerenex(TM) (ferric citrate), an oral, iron-based compound that has the capacity to bind to phosphate and form non-absorbable complexes. Zerenex has recently completed a Phase 2 clinical program as a treatment for hyperphosphatemia (elevated phosphate levels) in patients with end-stage renal disease, and Keryx is in the process of finalizing the U.S. Phase 3 program for Zerenex in consultation with the FDA. Keryx is headquartered in New York City.

Cautionary Statement

Some of the statements included in this press release, particularly those anticipating future clinical trials and business prospects for KRX-0401 (perifosine), may be forward-looking statements that involve a number of risks and uncertainties. For those statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. Among the factors that could cause our actual results to differ materially are the following: our ability to successfully and cost-effectively complete clinical trials for KRX-0401; the risk that the data (both safety and efficacy) from the Phase 3 trial will not coincide with the data analyses from the Phase 1 / 2 clinical trial previously reported by the Company; and other risk factors identified from time to time in our reports filed with the Securities and Exchange Commission. Any forward-looking statements set forth in this press release speak only as of the date of this press release. We do not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof. This press release and prior releases are available at

SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Keryx Biopharmaceuticals to Present at William Blair & Company Small-Cap Growth Stock Conference
2. Keryx Biopharmaceuticals, Inc. Announces Positive Preliminary Phase 2 Data on KRX-0401 in Patients with Chemo-Insensitive Rare Sarcoma
3. Keryx Biopharmaceuticals, Inc. Announces Phase 1 and Phase 2 Data on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Multiple Myeloma at 49th Annual Meeting of American Society of Hematology
4. Keryx Biopharmaceuticals Completes SUN-MICRO Phase 3 Pivotal Trial
5. Keryx Biopharmaceuticals Announces that the SUN-MICRO Phase 3 Clinical Trial Failed to Meet its Primary Efficacy Endpoint
6. Keryx Biopharmaceuticals Announces Termination of SUN-MACRO Phase 4 Trial
7. Keryx Biopharmaceuticals, Inc. Announces Poster Presentation Highlighting Observed Clinical Activity of KRX-0401 (Perifosine) at the American Society of Clinical Oncology Meeting in Chicago, Illinois
8. Keryx Biopharmaceuticals, Inc. Announces Phase 2 Results on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Waldenstroms Macroglobulinemia at the 44th Annual Meeting of the American Society of Clinical Oncology
9. Keryx Biopharmaceuticals, Inc. Reports Phase 1/2 Data on KRX-0401 (Perifosine) at 50th Annual Meeting of American Society of Hematology
10. Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data on KRX-0401 (Perifosine) in Combination with Bortezomib (+/- Dexamethasone) at the 12th International Multiple Myeloma Meeting
11. Keryx Biopharmaceuticals Reports Single Agent Phase 2 Data of KRX-0401 (Perifosine) Further Demonstrating KRX-0401s Activity in the Treatment of Advanced Metastatic Renal Cell Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2014)... , Aug. 22, 2014   Zacks Equity Research ... Bull of the Day and Panera (Nasdaq: PNRA - Free ... Equity Research provides analysis on Amicus Therapeutics (Nasdaq: FOLD - ... and Shire (Nasdaq: SHPG - Free Report ). ... Bull of the Day : The biotech ...
(Date:8/22/2014)... -- Research and Markets has announced the ... Industry Report 2014" report to their offering. ... Report 2014 is a professional and in-depth study on ... with a focus on the Chinese situation. The ... definitions, classifications, applications and industry chain structure. The particulate ...
(Date:8/22/2014)... JOLLA , Cali ., Aug. 22, ... International Papillomavirus Conference shows that a therapy being developed by ... the two that cause 70 percent of all cervical cancer. ... HTI-1968 blocked the replication of HPV-16, HPV-18 and HPV-11 cells, ... Thomas Broker , Ph.D., who presented the findings at the ...
Breaking Medicine Technology:Epizyme, Panera, Amicus Therapeutics, Sanofi and Shire highlighted as Zacks Bull and Bear of the Day 2Epizyme, Panera, Amicus Therapeutics, Sanofi and Shire highlighted as Zacks Bull and Bear of the Day 3Epizyme, Panera, Amicus Therapeutics, Sanofi and Shire highlighted as Zacks Bull and Bear of the Day 4Epizyme, Panera, Amicus Therapeutics, Sanofi and Shire highlighted as Zacks Bull and Bear of the Day 5Epizyme, Panera, Amicus Therapeutics, Sanofi and Shire highlighted as Zacks Bull and Bear of the Day 6Global and Chinese Particulate Respirators Industry Report 2014 2Study shows Hera Therapeutics experimental compound shuts down human papillomavirus that causes most cervical cancer 2
... 6 TargeGen, Inc. today announced that,the Company,s ... and the,Company plans to initiate a multi-center clinical ... highly selective JAK2 inhibitor in,January, 2008. Additionally, TargeGen ... will be made at the 2007 ASH Conference,(Atlanta, ...
... Inc. (Nasdaq: BCRX ) today provided an ... Forodesine HCl Data to be Presented at American ... Chair, Dermatology, The University of,Texas M.D. Anderson Cancer ... Phase I/II clinical study of oral forodesine HCl ...
Cached Medicine Technology:TargeGen Announces Planned Initiation of Clinical Trial of JAK2 Inhibitor TG101348 in Myeloproliferative Disease Patients, and Presentations at ASH 2BioCryst Provides Forodesine HCl Update 2BioCryst Provides Forodesine HCl Update 3BioCryst Provides Forodesine HCl Update 4BioCryst Provides Forodesine HCl Update 5
(Date:8/22/2014)... A new, online conference is coming August 25th-29th, 2014 ... and open to everyone. Over 20 top experts will ... on how to stop emotional eating, start eating healthier and ... is not a diet. The concept is about how to ... this, don't eat that" approach. , You can sign up ...
(Date:8/22/2014)... Women with severe disabilities and multiple chronic conditions are ... no disabilities or no chronic conditions, a new study ... than women with moderate disabilities or women with only ... affiliate scientist with the Li Ka Shing Knowledge Institute ... with disabilities often have other measures of social vulnerability, ...
(Date:8/22/2014)... August 22, 2014 For patients who need surgery ... cost-effective procedure is the least often used, reports a ... , official journal of the Congress of ... Lippincott Williams & Wilkins , a part of ... provides good pain relief at much lower cost than ...
(Date:8/22/2014)... 2014 ItsHot.com, a client-centric manufacturer, wholesaler ... off on its range of beautiful diamond heart pendants. ... Gold Hearts 14K White Rose Gold Diamond Heart Pendant, ... of 77%. Previously priced at $3,715.00, customers can now ... code of this mesmerizing pendant embedded with 0.66 carats ...
(Date:8/22/2014)... New York, NY (PRWEB) August 22, 2014 ... Theresa Caputo tickets in Kalamazoo, New Orleans, Albuquerque ... family after death, the “Long Island Medium,” Theresa Caputo, allows ... on Long Island. She is part of a close knit ... child. After speaking with a spiritual healer, realized she had ...
Breaking Medicine News(10 mins):Health News:20 Top Experts Discuss How to Unravel the Food-Mood Connection 2Health News:Women with severe, chronic health issues are screened for breast cancer less often 2Health News:More common procedures for painful facial tics carry high costs, reports study in Neurosurgery 2Health News:ItsHot.com Now Offers 60-80% Discount on its Striking Collection of Diamond Heart Pendants 2Health News:Theresa Caputo Tickets in Kalamazoo at Wings Stadium, Saenger Theatre in New Orleans, Kiva Auditorium in Albuquerque and Rapid City at Don Barnett Arena Now Available 2
... Amanda Gardner HealthDay Reporter , MONDAY, Oct. 11 ... higher risk for stroke even if they don,t have full-blown ... people who show signs of insulin resistance -- a reduction ... from the bloodstream -- may be helpful in preventing stroke, ...
... Health care in the last six months of life has ... among Medicare beneficiaries in the United States and older adults ... final six months of life in both countries, according to ... the February 14 print issue of Archives of Internal ...
... retinal conditions nearly doubled between 1997 and 2007, with ... performed, according to a report in the October issue ... JAMA/Archives journals. "Retinal disease is highly prevalent among ... diabetic retinopathy account for more than half the irreversible ...
... , MONDAY, Oct. 11 (HealthDay News) -- Pre-teens who spent ... TV or computer were at greater risk of having psychological ... kids also tended to be physically active, new research finds. ... November print issue of Pediatrics , found that the ...
... By Jenifer Goodwin HealthDay Reporter , ... have jaundice may be at higher risk of developing ... said far more research needs to be done before ... analyzed information from national registries that included all Danish ...
... disparities in the receipt of breast cancer care persist ... status. That is the conclusion of a study published ... of the American Cancer Society. The findings suggest that ... breast cancer care and to ensure that all affected ...
Cached Medicine News:Health News:Insulin Resistance Might Raise Risk of Stroke 2Health News:Insulin Resistance Might Raise Risk of Stroke 3Health News:End-of-life care patterns shift for patients with heart failure in both US and Canada 2Health News:End-of-life care patterns shift for patients with heart failure in both US and Canada 3Health News:End-of-life care patterns shift for patients with heart failure in both US and Canada 4Health News:End-of-life care patterns shift for patients with heart failure in both US and Canada 5Health News:Treatment of retinal conditions appears to have changed significantly in previous decade 2Health News:Could Excess Computer, TV Time Harm Kids Psychologically? 2Health News:Could Excess Computer, TV Time Harm Kids Psychologically? 3Health News:Danish Study Suggests Jaundice-Autism Link 2Health News:Danish Study Suggests Jaundice-Autism Link 3Health News:Insurance and socioeconomic status do not explain racial disparities in breast cancer care 2
... and fourth year medical students on ... easy access in a rapid-fire Q&A ... lab coat pocket, this reference is ... prior to surgical rounds as well ...
With its extensive content and custom-designed user interface, Schwartz Principles of Surgery, PDA Edition enables you quick access to the answers you need to make the right diagnosis or initiate a t...
This handy reference contains all of the essential information that surgical residents and medical students need to have at their fingertips for day-to-day patient care....
This book includes orthopedic, reproductive, renal, cardiovascular, GI, and respiratory problems; and other common conditions....
Medicine Products: